First-in-Human, Phase I Study of PCA062 in Solid Tumors-Letter

Bernadette de Rauglaudre; Pascal Finetti; David Jérémie Birnbaum; Marc Lopez; François Bertucci; Emilie Mamessier

doi:10.1158/1535-7163.MCT-22-0240

First-in-Human, Phase I Study of PCA062 in Solid Tumors-Letter

Mol Cancer Ther. 2022 Nov 3;21(11):1742-1743. doi: 10.1158/1535-7163.MCT-22-0240.

Authors

Bernadette de Rauglaudre^{1

2

3}, Pascal Finetti^{1

3}, David Jérémie Birnbaum^{1

3

4}, Marc Lopez^{1

3}, François Bertucci^{1

3

5}, Emilie Mamessier^{1

3}

Affiliations

¹ Laboratory of Predictive Oncology, Centre de Recherche en Cancerologie de Marseille, Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, "Equipe labellisee Ligue Contre le Cancer", Marseille, France.
² Departement d'Oncologie Digestive, Hopital de la Timone, Assistance Publique - Hopitaux de Marseille (APHM), Marseille, France.
³ Aix-Marseille University, France.
⁴ Departement de Chirurgie digestive, Hopital Nord, APHM, Marseille, France.
⁵ Departement d'Oncologie Medicale, Institut Paoli-Calmettes, Marseille, France.

PMID: 36325689
DOI: 10.1158/1535-7163.MCT-22-0240

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents* / therapeutic use
Clinical Trials, Phase I as Topic
Humans
Neoplasms* / drug therapy

Substances

Antineoplastic Agents